Dostarlimab after Chemoradiation in pts w/locally advanced unresected H&N carcinoma

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Patients with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Disease Types: Head and Neck

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Patients with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma 

For More Information:

https://clinicaltrials.gov/study/NCT06256588?term=dostarlimab%20in%20head%20and%20neck%20carcinomas&checkSpell=&rank=1